Syracuse

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

Archive ouverte

Gossec, Laure | Kerschbaumer, Andreas | Ferreira, Ricardo, J O | Aletaha, Daniel | Baraliakos, Xenofon | Bertheussen, Heidi | Boehncke, Wolf-Henning | Esbensen, Bente Appel | Mcinnes, Iain, B | Mcgonagle, Dennis | Winthrop, Kevin, L | Balanescu, Andra | Balint, Peter, V | Burmester, Gerd, R | Cañete, Juan, D | Claudepierre, Pascal | Eder, Lihi | Hetland, Merete Lund | Iagnocco, Annamaria | Kristensen, Lars Erik | Lories, Rik | Queiro, Rubén | Mauro, Daniele | Marzo-Ortega, Helena | Mease, Philip, J | Nash, Peter | Wagenaar, Wendy | Savage, Laura | Schett, Georg | Shoop-Worrall, Stephanie, J W | Tanaka, Yoshiya | van den Bosch, Filip, E | van der Helm-van Mil, Annette | Zabotti, Alen | van der Heijde, Désirée | Smolen, Josef, S

Edité par CCSD ; BMJ Publishing Group -

International audience. Objective New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. Results The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. Conclusion These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion